Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613819 | 0.76 | HSP90AA1 (0.43) | L3MBTL1HPGDMEN1KMT2AHTT | |
| SCHEMBL11060073 | 0.73 | GAA (0.43) | L3MBTL1HPGDMEN1KMT2AGAA | |
| SCHEMBL5139622 | 0.72 | IDH1 (0.41) | L3MBTL1HPGDMEN1KMT2AGAA | |
| SCHEMBL3647399 | 0.71 | NPC1 (0.61) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL2874801 | 0.71 | NPC1 (0.61) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL10848424 | 0.70 | KDM4E (0.39) | L3MBTL1HPGDMEN1KMT2AGAA | |
| SCHEMBL27731634 | 0.69 | NPC1 (0.40) | L3MBTL1MEN1KMT2AIDH1ALDH1A1 | |
| Hydrogen Sulfide SCHEMBL27801563 | 0.69 | NPC1 (0.59) | L3MBTL1HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL25954381 | 0.69 | ALDH1A1 (0.51) | L3MBTL1HPGDMEN1KMT2AGAA | |
| SCHEMBL6935644 | 0.68 | SMN1; SMN2 (0.54) | L3MBTL1HPGDMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224183-B1 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | AHMAD SALEEM (US) | 2005-06-23 | — | — | US | claimed |
| US-6887870-B1 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | claimed |
| CN-1468232-A | Heterocyclic sodium/proton exchange inhibitors and method | ����˹�ж�-����˹˹������˾ | 2004-01-14 | — | — | CN | claimed |
| EP-1224183-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1224183-B1 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | AHMAD SALEEM (US) | 2005-06-23 | — | — | US | disclosed |
| US-6887870-B1 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| CN-1468232-A | Heterocyclic sodium/proton exchange inhibitors and method | ����˹�ж�-����˹˹������˾ | 2004-01-14 | — | — | CN | disclosed |
| EP-1224183-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | NHERF1, SLC9A3, SLC9A1 | L3MBTL1 1613/4885HPGD 213/4885MEN1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.